Edition:
India

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

7.40USD
18 Sep 2020
Change (% chg)

$0.22 (+3.06%)
Prev Close
$7.18
Open
$7.27
Day's High
$7.44
Day's Low
$7.05
Volume
464,865
Avg. Vol
222,699
52-wk High
$15.43
52-wk Low
$3.60

Fuchs, Charles 

Dr. Charles S. Fuchs M.D. serves as Independent Director of the Company. Dr. Fuchs is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development, and conducts research assessing novel therapeutic approaches in oncology. Dr. Fuchs is the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the Yale Cancer Center and Physician-in-Chief of the Smilow Cancer Hospital since January 2017. He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute from July 2007 to December 2017. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health.

Basic Compensation

Total Annual Compensation, USD 40,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 87,122
Fiscal Year Total, USD 127,122

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy

3,769,930

Carlos Campoy

--

Amy Peterson

3,395,720

W. Michael Kavanaugh

1,477,000

Lloyd Rowland

1,097,840

Nick Galli

--
As Of  31 Dec 2019